AnaptysBio FY2024 EPS Forecast Lifted by Leerink Partnrs

AnaptysBio, Inc. (NASDAQ:ANAB) – Equities researchers at Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for AnaptysBio in a note issued to investors on Tuesday, November 5th. Leerink Partnrs analyst D. Risinger now anticipates that the biotechnology company will earn ($5.76) per share for the year, up from their previous estimate of ($6.48). The consensus estimate for AnaptysBio’s current full-year earnings is ($6.84) per share. Leerink Partnrs also issued estimates for AnaptysBio’s Q4 2024 earnings at ($1.30) EPS, Q1 2025 earnings at ($1.88) EPS, Q2 2025 earnings at ($1.69) EPS, Q3 2025 earnings at ($1.75) EPS, Q4 2025 earnings at ($1.07) EPS, FY2025 earnings at ($6.01) EPS, FY2026 earnings at ($4.16) EPS, FY2027 earnings at ($3.41) EPS and FY2028 earnings at ($2.87) EPS.

Several other brokerages also recently commented on ANAB. Truist Financial increased their price objective on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. Guggenheim increased their price target on AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Wedbush reaffirmed an “outperform” rating and set a $42.00 price objective on shares of AnaptysBio in a report on Wednesday. UBS Group increased their target price on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. boosted their price target on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $55.45.

AnaptysBio Price Performance

NASDAQ:ANAB opened at $21.31 on Friday. AnaptysBio has a one year low of $13.36 and a one year high of $41.31. The firm has a 50-day moving average of $32.66 and a 200-day moving average of $29.92.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The business had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million.

Insider Buying and Selling at AnaptysBio

In related news, CFO Dennis Mulroy sold 12,220 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $39.91, for a total value of $487,700.20. Following the transaction, the chief financial officer now owns 4,744 shares in the company, valued at approximately $189,333.04. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other AnaptysBio news, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of the stock in a transaction dated Wednesday, August 14th. The shares were bought at an average price of $36.50 per share, with a total value of $9,999,978.00. Following the completion of the transaction, the insider now directly owns 7,794,996 shares in the company, valued at approximately $284,517,354. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Dennis Mulroy sold 12,220 shares of AnaptysBio stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the transaction, the chief financial officer now owns 4,744 shares of the company’s stock, valued at $189,333.04. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,440 shares of company stock worth $892,936 over the last three months. 33.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On AnaptysBio

Institutional investors have recently made changes to their positions in the stock. Intech Investment Management LLC purchased a new stake in AnaptysBio during the 3rd quarter worth about $229,000. Jennison Associates LLC bought a new stake in AnaptysBio during the 3rd quarter worth approximately $8,874,000. Victory Capital Management Inc. lifted its stake in AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after purchasing an additional 206,750 shares in the last quarter. GSA Capital Partners LLP bought a new position in AnaptysBio in the 3rd quarter valued at $574,000. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of AnaptysBio by 81.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 2,600 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.